Research & Education
Health Care Professionals
Patients
Gynecological Cancers
Your gynecological cancer team
Cervical Cancer
Each year, over 9,000 women are diagnosed with cancer of the cervix. At Scott and White, we see an average of three new cervical cancers every month.
The treatment for cervical cancer depends on the stage the cancer is in when it is diagnosed. There are four stages of cervical cancer. The staging process is done clinically, not surgically. We utilize the expertise of our gynecologic oncologists as well as technical information, to include CT scans and PET scans to assist us in the staging of our patients.
At Scott and White, we offer state-of-the-art treatment for all stages of cervical cancer, to include various types of surgical options , external beam radiation , implant radiation or brachytherapy and chemotherapy .
Learn more...
Additional resources on gynecologic cancers
Uterine Cancer
Uterine cancer is the most common invasive gynecologic cancer . At Scott and White, we treat an average of seven new uterine cancers every month.
Cancer of the uterus is diagnosed clinically, usually with a biopsy or with a dilation and curettage (D&C). Staging for uterine cancer is done surgically. Surgery usually consists of a total hysterectomy, removal of both tubes and ovaries and sampling of lymph nodes in the area.
Often times, surgery alone can be curative of uterine cancer. If further treatment is necessary, we offer state-of-the-art care in radiation therapy as well as chemotherapy.
Ovarian Cancer
Ovarian cancer lends itself very well to a multi-modality team approach. At any given time at Scott & White, we have approximately 40-50 patients who are actively being treated for ovary cancer.
Ovarian cancer is generally diagnosed both clinically and with imaging. We have an outstanding imaging center that has all modalities available to include Fastrak CT, MRI and PET scans.
Surgical therapy is necessary for diagnosis, staging and debulking.
Debulking procedures are unique to the management of ovary cancer because we are fortunate that ovarian cancer generally is chemotherapy sensitive. Frequently debulking procedures are extensive and we are supported very well with the surgical capabilities as well as the critical care capabilities for perioperative support.
The surgical capabilities consist of gynecologic oncologists, surgical oncologists, as well as colorectal surgeons. Following surgery, the majority of these patients require chemotherapy. The standard historically has been IV chemotherapy , although intraperitoneal therapy is on the forefront and we have been actively involved in some of the initial studies with intraperitoneal therapy through the Gynecology Oncology Group and the Southwest Oncology Group.
In addition, some of the newer biologic agents such as Avastin are being incorporated into these treatment regimens. Our patients are encouraged to participate in phase III group trials through the Gynecology Oncology Group and we have a full range of support to include expertise and palliative therapy, interventional pulmonologists, etc.
Bookmark this Page
Print this Page
Resize Text
